Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
Diginex Limited Announces 57% Increase in Revenues and Transformed Balance Sheet for Fiscal Year ended March 31, 2025
LONDON, July 11, 2025 (GLOBE NEWSWIRE) -- Diginex Limited (“Diginex” or the…